Oct 2026· Medicine· Vol 105, pp. e51073· 0 citations· 28 references
Medicine
TL;DR
Higher peripheral blood CTPC levels were associated with greater BM tumor burden and more abnormal routine laboratory markers in patients with newly diagnosed MM, and CTPC quantification may serve as an adjunctive marker for baseline disease assessment in regional clinical settings.
Abstract
Circulating tumor plasma cells (CTPCs) detected by multiparameter flow cytometry may serve as a minimally invasive marker of disease burden in multiple myeloma (MM). However, the relationship between CTPC burden, routine laboratory parameters, and bone marrow (BM) involvement remains insufficiently characterized in regional clinical settings. This retrospective single-center study included 51 consecutive patients with newly diagnosed MM. Peripheral blood CTPCs were quantified using ten-color flow cytometry. Among them, 41 patients with evaluable CTPC data were stratified into CTPC-higher (n = 20) and CTPC-lower (n = 21) groups using a 0.07% cutoff. Laboratory variables and immunophenotypic features were compared between groups, and correlations were assessed using Spearman rank analysis. Exploratory logistic regression adjusted for age and sex was performed, and Benjamini–Hochberg false-discovery-rate correction was applied to multiple comparisons. Compared with the CTPC-lower group, the CTPC-higher group had lower hemoglobin levels (73.5 vs 107.0 g/L; P < .001), lower albumin levels (30.9 vs 38.2 g/L; P = .006), higher β2-microglobulin levels (6.97 vs 3.25 mg/L; P = .004), and higher BM plasma cell percentages on smear examination (34.75% vs 12.00%; P = .005). CTPC levels were positively correlated with BM plasma cell percentage on smear examination (ρ = 0.67; P < .001) and negatively correlated with hemoglobin levels (ρ=−0.68; P < .001). These group differences and correlations remained significant after false-discovery-rate correction (all q ≤ 0.018). In age- and sex-adjusted analyses, hemoglobin, albumin, β2-microglobulin, and BM plasma cell percentage on smear remained associated with CTPC-higher status. Higher peripheral blood CTPC levels were associated with greater BM tumor burden and more abnormal routine laboratory markers in patients with newly diagnosed MM. CTPC quantification may serve as an adjunctive marker for baseline disease assessment in regional clinical settings. These cross-sectional findings from this limited sample do not establish prognostic value.
BACKGROUND
Tumor informed circulating tumor DNA (ctDNA) assays, such as Signatera, may improve risk stratification and treatment monitoring in urothelial cancer. However, their prognostic utility in metastatic urothelial cancer (mUC) is poorly defined. We evaluated the association between quantitative Signatera ctDNA a...
Alexander B. Karol, A. Argulian, Ruveyda Ayasun et al.· Clinical Genitourinary Cance...· 0 citations
Introduction. Multiple myeloma (MM) is a clinical condition characterized by clonal expansion of plasma cells that leads to end-organ damage, referred to as a myeloma-defining event, warranting initiation of therapy. Purpose. To evaluate prognostic impact of CD56 and CD117 expression in newly diagnosed MM. Materials an...
S. Mohammed, M. Mustafa, I. A. I. Agha· Лабораторная диагностика. Во...· 0 citations
Bone-marrow-based gene methylation markers may act as candidate epigenetic biomarkers for risk stratification in DLBCL, but results cannot yet support direct clinical judgement for hematopoietic stem cell transplantation.
Tian-Hua Zhao, Jing-Jing Liu, Li-Ping Geng et al.· Leukemia research : a Forum...· 0 citations
Background Plasma circulating tumor DNA (ctDNA) is a minimally invasive biomarker in head and neck squamous cell carcinoma (HNSCC). Most commercially available assays for human papillomavirus-unrelated HNSCC are tumor-informed assays that require tissue sampling and may not comprehensively capture tumor heterogeneity....
E. Sim, D. Ruiz-Torres, Pan Du et al.· The journal of liquid biopsy· 0 citations
Objectives: Minimally invasive biomarkers for risk stratification in early breast cancer are lacking. We examined whether pretreatment circulating natural killer (NK)-cell subsets, specifically CD107a+ NK cells, are associated with clinicopathological features and outcomes of early breast cancer and whether tumor trans...
Ying-Wen Su, Sheng-Hsiang Lin, Chi-Hui Hsu et al.· Cancers· 0 citations
Immune dysregulation is involved in multiple myeloma (MM) pathogenesis and progression yet current staging systems do not incorporate indicators of immune status. We retrospectively included 260 newly diagnosed multiple myeloma (NDMM) patients with baseline data of peripheral blood (PB) lymphocyte subsets and cytokines...
Xiang-Hong Zhao, Zhao-Yun Liu, Gonga Qin et al.· British Journal of Haematolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.